Safety and effects of SGLT-2 inhibitor use among LVAD patients with type 2 diabetes mellitus

被引：7

作者：

Cagliostro, Matthew ^{[1
]}

Hundal, Prabhjot ^{[2
]}

Ting, Peter ^{[1
]}

Patel, Sonika ^{[1
]}

Sudarshan, Sangita ^{[2
]}

Thomas, Jordan ^{[2
]}

Morris, Kathleen ^{[2
]}

Mancini, Donna M. ^{[1
,3
,4
]}

Moss, Noah ^{[1
,3
]}

Lala, Anuradha ^{[1
,3
,4
]}

Ravichandran, Ashwin ^{[2
]}

Mitter, Sumeet S. ^{[1
,3
,5
]}

机构：

[1] Icahn Sch Med Mt Sinai, Mt Sinai Hosp, New York, NY 10029 USA

[2] Ascens St Vincent, Indianapolis, IN USA

[3] Mt Sinai Hosp, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA

[4] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, New York, NY USA

[5] 1190 5th Ave,Box 1030, New York, NY 10029 USA

来源：

AMERICAN HEART JOURNAL PLUS: CARDIOLOGY RESEARCH AND PRACTICE | 2022年 / 18卷

关键词：

SGLT2 inhibitors (SGLT2i); Heart failure; Left ventricular assist device (LVAD);

D O I：

10.1016/j.ahjo.2022.100154

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

SGLT-2 inhibitors have been shown to confer reduced risk of adverse cardiovascular events in patients with heart failure, and have also been studied preliminarily among heart transplant patients, with overall positive findings. Use of SGLT-2 inhibitors among patients with durable mechanical circulatory support has not been studied. Here we present our results from a combined retrospective cohort of LVAD patients on SGLT-2 inhibitors at two major academic centers, which showed a good safety profile but prompted questions for further investigation. We advocate for further research into the safety and impact of SGLT-2 inhibitors among LVAD patients.

引用

页数：4

共 50 条

[1] Effects Of Sglt-2 Inhibitor Use Among LVAD Patients
Al Ali, Omar Tayseer
Pendela, Venkata Satish
Babayale, Omofolarin
Faisaluddin, Mohammed
Parikh, Vishal
JOURNAL OF CARDIAC FAILURE, 2024, 30 (01) : 205 - 205
[2] Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus
El Hage, Lea
Kashyap, Sangeeta R.
Rao, Pratibha
JOURNAL OF PRIMARY CARE AND COMMUNITY HEALTH, 2019, 10
[3] Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus
Santos, Leyna Leite
Camello De Lima, Fernando Jose
De Sousa-Rodrigues, Celio Fernando
Barbosa, Fabiano Timbo
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2017, 63 (07): : 636 - 641
[4] Individualizing Treatment With SGLT-2 Inhibitor Therapy in Type 2 Diabetes Mellitus
Miller, Eden M.
JOURNAL OF FAMILY PRACTICE, 2017, 66 (02): : S13 - S16
[5] Overview of the Efficacy and Safety of SGLT-2 Inhibitors in Type 2 Diabetes Mellitus
Miller, Eden M.
JOURNAL OF FAMILY PRACTICE, 2017, 66 (02): : S5 - S12
[6] Remogliflozin: the new low cost SGLT-2 inhibitor for type 2 diabetes mellitus
Atal, Shubham
Fatima, Zeenat
Singh, Sakshi
Balakrishnan, Sadasivam
Joshi, Rajnish
DIABETOLOGY INTERNATIONAL, 2021, 12 (03) : 247 - 253
[7] Remogliflozin: the new low cost SGLT-2 inhibitor for type 2 diabetes mellitus
Shubham Atal
Zeenat Fatima
Sakshi Singh
Sadasivam Balakrishnan
Rajnish Joshi
Diabetology International, 2021, 12 : 247 - 253
[8] Ertugliflozin: A New Option in the SGLT-2 Inhibitor Market for the Treatment of Type 2 Diabetes Mellitus
Powell, Jason
Garland, Scott G.
ANNALS OF PHARMACOTHERAPY, 2019, 53 (05) : 478 - 485
[9] Excess weight loss in a patient with type 2 diabetes mellitus treated with an SGLT-2 inhibitor
Cichocka, Edyta
Gumprecht, Janusz
ENDOKRYNOLOGIA POLSKA, 2019, 70 (06) : 522 - 523
[10] Efficacy and Safety of SGLT-2 Inhibitors in Heart Failure Patients with Diabetes Mellitus
Kubota, Yoshiaki
A, K.
Y, A.
I, Y.
M, K.
T, Y.
Y, M.
T, Y.
S, W.
JOURNAL OF CARDIAC FAILURE, 2015, 21 (10) : S202 - S202

← 1 2 3 4 5 →